<span item_type="fundamental" item_id="8c1254e5967f6198e6f35ba3452e56b5" counter_id="ST/US/CKPT" env="prod"></span><span item_type="announcement" item_id="515749971701601537" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -0.19.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Revenue - Related Party</strong>: No revenue was recognized for the three months ended March 31, 2025, and 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1651407/000141057825001233/ckpt-20250331x10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The net loss for the three months ended March 31, 2025, was $11.2 million, compared to $10.9 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1651407/000141057825001233/ckpt-20250331x10q.htm"></span></li><li><strong>Operating Expenses</strong>: Total operating expenses for the three months ended March 31, 2025, were $11.1 million, compared to $10.9 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1651407/000141057825001233/ckpt-20250331x10q.htm"></span></li><li><strong>Research and Development Expenses</strong>: R&amp;D expenses decreased to $3.8 million for the three months ended March 31, 2025, from $8.5 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1651407/000141057825001233/ckpt-20250331x10q.htm"></span></li><li><strong>General and Administrative Expenses</strong>: G&amp;A expenses increased to $7.4 million for the three months ended March 31, 2025, from $2.5 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1651407/000141057825001233/ckpt-20250331x10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: Net cash used in operating activities was $11.7 million for the three months ended March 31, 2025, compared to $6.5 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1651407/000141057825001233/ckpt-20250331x10q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: Net cash provided by financing activities was $38.1 million for the three months ended March 31, 2025, compared to $12.8 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1651407/000141057825001233/ckpt-20250331x10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Cash and Cash Equivalents</strong>: Cash and cash equivalents were $33.0 million as of March 31, 2025, compared to $6.6 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1651407/000141057825001233/ckpt-20250331x10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to use proceeds from previous financing transactions primarily for general corporate purposes, including financing growth, developing new or existing product candidates, and funding capital expenditures, acquisitions, and investments.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1651407/000141057825001233/ckpt-20250331x10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is involved in a merger agreement with Sun Pharmaceutical Industries, Inc., which is expected to close in the second quarter of 2025. This merger is anticipated to facilitate the commercialization and launch of UNLOXCYT in the U.S. and potentially other markets worldwide.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1651407/000141057825001233/ckpt-20250331x10q.htm"></span></li></ul>

Checkpoint Therap | 10-Q: FY2025 Q1 EPS: USD -0.19